Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2019

View Archived Issues

An inclusive look at the microbiome

NGM reports promising interim results from ongoing phase II study of aldafermin in NASH

Xoc Pharmaceuticals launches phase I study of XC101-D13H

New mouse model of diabetic cystopathy described

Discovery of novel potent fully human FVIII mimetic BiAb, KY-1049

Selepressin does not improve vasopressor- and ventilator-free days in patients with septic shock

Preliminary data presented from phase I/II ASPIRO study of AT-132

MinL4.0 RSV: a synthetic, live-attenuated vaccine against respiratory syncytial virus

MTPS-9579A dose-dependently inactivates airway tryptase for the treatment of asthma

FDA approves Wilate for hemophilia A

Tezepelumab reduces activation of matrix remodeling and inflammatory pathways

Scenesse wins approval in U.S. for erythropoietic protoporphyria

GSK and Lyell Immunopharma collaborate to improve cell therapies for cancer

Faron receives DMC feedback for phase I/II MATINS trial of Clevegen

U.S. researchers patent ATR kinase inhibitors

University of California discloses new VLA-2 antagonists

Pfizer identifies antibacterial agents

Hinova Pharmaceuticals details compounds for cancer

New ALK kinase inhibitors revealed in University of Michigan patent

New CRISPR-Cas9 variant may boost gene-editing precision

AZD-4205 begins phase I/II study in Korea for peripheral T-cell lymphoma

Incyte initiates phase I/II study of INCB-001158 with daratumumab in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...